Analyst Price Targets — EVH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 6:23 pm | — | Truist Financial | $6.00 | $3.05 | TheFly | Evolent Health price target lowered to $6 from $10 at Truist |
| February 25, 2026 2:20 pm | Sean Dodge | BMO Capital | $3.50 | $3.03 | StreetInsider | Evolent Health (EVH) PT Lowered to $3.50 at BMO Capital |
| February 2, 2026 12:14 pm | David Larsen | BTIG | $10.00 | $3.21 | TheFly | Evolent Health price target lowered to $10 from $16 at BTIG |
| December 2, 2025 3:16 pm | — | Piper Sandler | $6.00 | $3.84 | StreetInsider | Evolent Health (EVH) PT Lowered to $6 at Piper SandlerMember Login |
| January 16, 2025 1:53 am | Kevin Caliendo | UBS | $14.00 | $9.97 | TheFly | Evolent Health price target lowered to $14 from $27 at UBS |
| January 15, 2025 8:59 pm | Jailendra Singh | Truist Financial | $20.00 | $9.97 | TheFly | Evolent dips after Truist warns guidance may be 'significantly' below consensus |
| January 14, 2025 3:36 pm | Sean Dodge | RBC Capital | $17.00 | $11.96 | StreetInsider | Evolent Health (EVH) PT Lowered to $17 at RBC Capital as Membership Declines |
| January 10, 2025 12:14 pm | Constantine Davides | JMP Securities | $18.00 | $12.54 | TheFly | Evolent Health price target lowered to $18 from $27 at JMP Securities |
| November 18, 2024 12:41 pm | Mohan Naidu | Oppenheimer | $28.00 | $12.59 | StreetInsider | Evolent Health (EVH) PT Lowered to $28 at Oppenheimer |
| October 17, 2024 2:58 pm | Jeff Garro | Stephens | $38.00 | $24.96 | TheFly | Evolent weakness linked to elevated Medicaid MLRs at peers, says Stephens |
Latest News for EVH
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences. A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor…
Evolent Health, Inc. is rated a Buy, with turnaround momentum and risk/reward now favoring upside after recent operational and strategic shifts. EVH's Performance Suite model now covers ~90% of revenue, offering risk protection and greater earnings predictability, despite near-term profit headwinds from new contract launches. Oncology drives EVH's growth, with strong customer retention (>98%) and cost discipline via…
Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EVH.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.